Alzheimer's Association Launches $100 Million PROTECT-Cog Trial

The study aims to recruit older adults at high risk for cognitive impairment to compare two distinct lifestyle programs—one featuring intensive coaching and another with lighter support. Researchers will introduce drugs such as GLP-1 receptor agonists into the regimen, testing whether these medications, already linked to potential neurological benefits, can amplify the protective impact of diet, exercise, and cardiovascular health. Participants will be monitored over a three-year period, with comprehensive health and cognitive assessments performed every six months to measure changes in brain function and overall frailty.

This project follows the U.S. POINTER study, which previously demonstrated that structured lifestyle modifications could provide a significant cognitive advantage for older Americans. While real-world data suggests GLP-1 agonists might reduce dementia risk by as much as 40–70% in certain populations, the new trial seeks to provide rigorous, controlled evidence for their role in prevention. Maria C. Carrillo, the study's principal investigator, noted that the initiative targets the critical window before symptoms emerge, aiming to identify how these dual-action strategies can most effectively preserve cognitive health.